INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo PLATO-25 TABLETS

SCHEDULING STATUS:
S3

PROPRIETARY NAME
(and dosage form):

PLATO-25 TABLETS

COMPOSITION:
Each tablet contains 25 mg of
dipyridamole.
This product contains Tartrazine.

PHARMACOLOGICAL CLASSIFICATION:
A.8 Medicines acting on blood and haemopoietic systems.

PHARMACOLOGICAL ACTION:
Dipyridamole is readily absorbed from the gastro-intestinal tract. It reduces platelet adhesiveness and aggregation. It reduces permeability of the red cell membrane to adenosine. Intracellular interaction between adenosine and ATP is inhibited, thus less ADP is formed. As a result of this mechanism the ADP induced aggregation and adhesiveness is reduced.

INDICATIONS:
Conditions where reduction in platelet aggregation and/or adhesiveness is considered to be of therapeutic benefit.

CONTRA-INDICATIONS:
Hypersensitivity. Patients with hypotension following myocardial infarction.

WARNING:
This product contains FD and C Yellow No. 5 (Tartazine) which may cause allergic type reactions (including Bronchial Asthma) in certain susceptible individuals. Although the overall incidence of Tartrazine sensitivity in the general population is currently thought to be low, it is frequently seen in patients who also have aspirin sensitivity.

DOSAGE AND DIRECTIONS FOR USE:
Four tablets four times a day (usually four tablets three times a day and four at bedtime). Where possible, dosage should commence with four tablets in the morning and evening for 5 days, four three times a day for 5 days and then four times a day. Aspirin potentiates the effect of dipyridamole and a reduction in dosage may be necessary.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Headache, vertigo, nausea, vomiting, skin rash, diarrhoea, flushing and a bitter taste, have been reported.
Dipyridamole can induce angina in patients.
Dipyridamole should be given with care to patients with hypotension.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
As under "Side-effects". Treatment is symptomatic and-supportive.

IDENTIFICATION:
Orange coated tablets.

PRESENTATION:
Securitainers of 100 tablets.

STORAGE INSTRUCTIONS:
Protect from moisture, store below 25°C.
KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER:
N/8/163.

NAME AND BUSINESS ADDRESS OF APPLICANT:
Lennon Limited
7 Fairclough Road
PORT ELIZABETH
6001

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
11.8.1986 M652

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996,1997,1998